Engineering iPSC for Cancer Immunotherapy

Induced pluripotent stem cells (iPSCs) have the ability to differentiate into various cell types, including immune cells such as T cells and natural killer cells. iPSCs hold great promise for developing safer, more effective, and personalized cell therapies with broader applicability in the treatment of various diseases. iPSCs can be engineered using manipulation techniques to achieve specific characteristics or functions. Once engineered, iPSCs can be directed to differentiate into specific cell types using various differentiation protocols. At Creative Biolabs, our mission is to deliver innovative solutions to genetically engineer iPSCs for applications in cell therapy and regenerative medicine.

Fig.1 Schematic overview of iPSC-derived allogeneic cell therapy.¹

iPSC Engineering Platform

Creative Biolabs maintains a strong competitive edge in the field of iPSC research and development. Our innovative platform has allowed us to establish a comprehensive and diverse collection of iPSC lines, which serve as an invaluable resource for research and therapeutic applications. Our team of experienced scientists is dedicated to providing our clients with the most advanced and effective iPSC-based solutions. By leveraging our expertise in iPSC biology, we have developed efficient strategies to engineer iPSCs and differentiate them into specific cell types. Our platform utilizes a series of well-established and validated techniques for single-cell isolation, clonal expansion, and cell characterization, enabling the generation of large quantities of identical iPSC derivatives for diverse applications.

Services

At Creative Biolabs, we provide iPSC reprogramming from human or non-human samples, iPSC engineering services, and iPSC differentiation services. Our experts have the experience and optimized protocols to introduce a variety of genetic modifications in iPSCs. Leveraging our efficient genome editing technology, engineered iPSCs can be obtained in just a few weeks. Our protocols have been optimized for efficiently differentiating engineered iPSCs into a variety of cell types, such as NK cells, T cells, and dendritic cells.

Q&A

1. Could you provide services for reprogramming primary cells into iPSCs?

Yes. We generate iPSCs through many different reprogramming technologies. For example, we use Sendai virus, a non-integrating RNA virus, to reprogram iPSCs.

2. Do you provide engineering services using our iPSCs?

Yes. We engineer iPSCs from customers or Creative Biolabs.

3. Do you provide monocyte differentiation service from iPSCs?

Yes. We offer comprehensive service for iPSC differentiation into various cell types. If the cell type of interest is not listed, please contact us.

Reference

1. Zhou, Yang, et al. "Engineering induced pluripotent stem cells for cancer immunotherapy." Cancers 14.9 (2022): 2266.

For Research Use Only | Not For Clinical Use